Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis
Open Access
- 1 June 2015
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 33 (28), 3193-3199
- https://doi.org/10.1016/j.vaccine.2015.05.001
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 24 references indexed in Scilit:
- Clinical and Economic Burden of Community-Acquired Pneumonia among Adults in the Czech Republic, Hungary, Poland and SlovakiaPLOS ONE, 2013
- Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisBMJ, 2012
- Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009European Respiratory Journal, 2012
- Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the USVaccine, 2011
- The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003–2007)Vaccine, 2011
- Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the NetherlandsClinical Therapeutics, 2010
- Clinical and economic burden of community-acquired pneumonia among adults in EuropeThorax, 2010
- Burden of Community-Acquired Pneumonia in North American AdultsPostgraduate Medicine, 2010
- New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare qualityThorax, 2009
- Increasing Hospital Admissions for Pneumonia, EnglandEmerging Infectious Diseases, 2008